Toronto, Ontario–(Newsfile Corp. – March 29, 2022) – ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) (“ScreenPro” or the “Company”) is pleased to announce that the Company’s wholly owned subsidiary, Add Biomedical Inc. (Add Bio), is strengthening its library of intellectual property (IP). The Company has applied for the Cancer Antigen (CA) 15-3 rapid testing kit for breast cancer screening to the United States Patent and Trademark Office (USPTO).
Breast cancer is the world’s most commonly occurring cancer. According to Cancer.ca, breast cancer is the second leading cause of cancer deaths in Canadian women. Recent reports show that 76 Canadian women are diagnosed with breast cancer everyday and on average, 15 of those women die from the disease everyday. (Source: Canadian Cancer Society)
The CA 15-3 screening test can detect early-stage breast cancer before it develops and therefore it can significantly reduce the lethal rate and risk to patients.
“In the midst of the ever-changing pandemic environment, we cannot ignore other infectious diseases that require early diagnosis screening. As we investigate IP testing kits for the North American marketplace, we are pleased to be starting our expansion with pursing the CA 15-3 breast cancer testing kit. We have helped the community navigate through this pandemic with Covid testing and look to do the same with breast cancer screening.”, said Lena Kozovski, CEO of the Company.
“ScreenPro has been making strides in creating value for its shareholders with continued strength in Covid testing in the film and production industry as well as the company’s recent diversification of product offerings. US patent applications and other opportunistic strategies are some of the ways that the company will continue to be innovative in protecting and growing value for our shareholders. We continue to build momentum and look forward to growing our shareholder value in 2022.”, said Michael Yeung, Chairman of the Company.
ScreenPro is a Screening and Medical Technology company that provides turnkey screening solutions with its proprietary medical alerting software. ScreenPro’s unique access to multiple manufacturers of high-quality test kits and its strategic partnership with labs in British Columbia, Ontario and Quebec allows ScreenPro to be a full-service nationwide provider of COVID testing and breast cancer screening solutions across Canada. In addition, ScreenPro has its own medical doctor and nursing professionals with on the ground support staff and transportation, with access to high quality PPEs to ensure that clients are protected in all aspects of their testing needs.
For additional information on ScreenPro and other corporate information, please visit the Company’s website at www.screenprosecurity.com
About Add Biomedical
ScreenPro’s wholly owned subsidiary, Add Biomedical is a biomedical screening company specialized in creating solutions for disease diagnosis. ScreenPro has exclusively purchased the Canadian entity of AddBiomedtiek Co, Korea, which gives the Company exclusive rights to their products within the North American marketplace. Acquiring Add Biomedical gives the Company access to a library of products. Currently, the Company has an interest to bring the CA 15-3 Rapid Test Kit’s for breast cancer screening into the North American marketplace as well as Veterinary Animal Disease and Infectious Disease screening tests. The technology is easy to use, fast, portable, cost effective and can be operated in resource limited areas. Add Biomedical is committed to early diagnosis which can saves lives.
For additional information on Add Biomedical and other corporate information, please visit the Company’s website at: www.addbiomedical.com
For more information about the Company, please refer to the Company’s profile on SEDAR at www.sedar.com.
Neither the Canadian Securities Exchange (the “CSE”) nor it’s Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
For further information please contact:
Lena Kozovski, CEO
Certain statements contained in this news release may constitute forward‐looking information, including statements relating to expectations regarding the acquisition and business of Concierge Medical Consultants Inc. and the future development of ScreenPro’s business. Forward‐looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward‐looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward‐looking information. The actual results of ScreenPro could differ materially from those anticipated in this forward‐looking information as a result of regulatory decisions, competitive factors in the industries in which ScreenPro operates, prevailing economic conditions, changes to ScreenPro’s strategic growth plans, and other factors, many of which are beyond the control of ScreenPro. Management of ScreenPro believes that the expectations reflected in the forward‐looking information herein are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward‐looking information should not be unduly relied upon. Any forward‐looking information contained in this news release represents ScreenPro’s expectations as of the date hereof and is subject to change after such date. ScreenPro disclaims any intention or obligation to update or revise any forward‐looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/118447